New bladder cancer drug safety checked in indian patients

NCT ID NCT06862219

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Feb 04, 2026 · Last updated May 01, 2026 · Updated 11 times

Summary

This study is for Indian adults with advanced or metastatic urothelial cancer (bladder cancer that has spread). The main goal is to confirm the safety of the drug enfortumab vedotin. Participants will receive the drug through an IV infusion every 28 days. The study will monitor for side effects and check how well the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site IN91001
RECRUITING

Surat, India
Site IN91004
RECRUITING

Mumbai, Maharashtra, India
Site IN91005
RECRUITING

Varanasi, Uttar Pradesh, India
Site IN91008
RECRUITING

Mumbai, India
Site IN91009
RECRUITING

Nagpur, India
Site IN91010
RECRUITING

Bhubaneswar, India
Site IN91012
RECRUITING

Ahmedabad, India
Site IN91015
RECRUITING

Kochi, Kerala, India
Site IN91016
RECRUITING

New Delhi, National Capital Territory of Delhi, India
Site IN91017
RECRUITING

Dumas, Surat, India

Conditions

Explore the condition pages connected to this study.

METASTATIC UROTHELIAL CARCINOMA